Arm A is subdivided into three cohorts: cohort A-1 (Ziftomeniob + FLAG-IDA), cohort A-2 (Ziftomenib plus LDAC), and cohort A-3 (Ziftomenib plus Gilteritinib in NPM1/FLT3 double mutant AML). Here, FLT3 is linked to acute myeloid leukemia.